Clinical trial
Safety and Dose Study of GRN163L Administered to Patients With Refractory or…
NCT00310895 · Geron Corporation, Industry · Completed
Key facts
| NCT number | NCT00310895 |
|---|---|
| Title | Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies |
| Official title | A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and MTD of GRN163L in Patients With Refractory or Relapsed Solid Tumor Malignancies |
| Lead sponsor | Geron Corporation, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumor Malignancies |
| Intervention type | Drug |
| Interventions | Imetelstat Sodium (GRN163L) |
| Enrollment | 85 |
| Start date | Mar 1, 2006 |
| Primary completion | Mar 1, 2013 |
| Completion | Mar 1, 2013 |
| First posted | Apr 5, 2006 |
| Last update posted | Dec 24, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: